Treatment of Advanced Renal Cell Carcinoma with Sarcomatoid Predominant Histology
Advanced renal cell carcinoma that presents with sarcomatoid predominant histology represents a distinct and aggressive clinical scenario. The histological subtype directly informs which treatment strategies are appropriate at first line.
Clinical Scenario
This protocol applies to patients with advanced renal cell carcinoma in whom the tumour demonstrates sarcomatoid predominant histology — a finding that guides the selection of systemic therapy.
Treatment Approach (Partial)
Immune checkpoint inhibitor (ICI)-based combination therapy is the preferred approach for this population. Alternative options exist for patients who have contraindications to ICI-based regimens.
Full regimen details, sequencing, and eligibility criteria are available in the complete protocol ↓
References
- ICI-based therapies including ipilimumab+nivolumab, axitinib+pembrolizumab, cabozantinib+nivolumab and lenvatinib+pembrolizumab are preferred for advanced RCC with sarcomatoid (predominant) histology.
- Sunitinib and pazopanib are alternative options for patients with contraindications to ICI-based therapy.
DOI: 10.1016/j.annonc.2024.05.537
View source ↗